Paper Details

  1. Home
  2. Paper Details

Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia.

Author: AllenLee F, ChojnowskiKrzysztof, JamiesonBrian D, JurczakWojciech, KrawczykKatarzyna, MayerJiří, TianWei

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Avatrombopag was shown to be effective in treating chronic immune thrombocytopenia (ITP) in adults with platelet counts less than 30 × 10^9/L. The medication was superior to placebo in increasing platelet counts and reducing the need for other medications. The most common side effects were headache and contusion.
Paper Details　
Original Abstract of the Article :
Avatrombopag, an oral thrombopoietin receptor agonist, was compared with placebo in a 6-month, multicentre, randomised, double-blind, parallel-group Phase 3 study, with an open-label extension phase, to assess the efficacy and safety of avatrombopag (20 mg/day) in adults with chronic immune thr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282556/

データ提供：米国国立医学図書館（NLM）

Avatrombopag: A Novel Thrombopoietin Receptor Agonist for Chronic Immune Thrombocytopenia

In the vast desert of medical research, scientists are constantly searching for oases of effective treatments. This study delves into the realm of hematology, focusing on a specific oasis – Avatrombopag, a novel oral thrombopoietin receptor agonist. It acts like a camel guide, leading platelets to their destination, increasing their count in patients with chronic immune thrombocytopenia (ITP). The study, conducted as a Phase 3 randomized, double-blind, parallel-group trial, aimed to assess the efficacy and safety of Avatrombopag compared to a placebo. The results revealed that Avatrombopag significantly increased platelet count in patients with ITP, suggesting a promising therapeutic avenue for this challenging condition.

Avatrombopag Outperforms Placebo in Increasing Platelet Count

The results showed that Avatrombopag was superior to placebo in increasing platelet count. The median cumulative number of weeks of platelet response was significantly higher in the Avatrombopag group (12.4 weeks) compared to the placebo group (0.0 weeks). This difference is like the difference between a camel caravan traversing a vast desert for months and one that is stuck in the same spot. Furthermore, a greater platelet response rate was observed at day 8 for patients treated with Avatrombopag compared to placebo (65.63% vs. 0.0%).

Avatrombopag: A Well-Tolerated Treatment Option

The safety profile of Avatrombopag was found to be consistent with previous studies, indicating a well-tolerated medication. The most common adverse events were headache and contusion, which are like minor bumps in the road during a long desert journey. Overall, this study offers a ray of hope for patients with ITP, showcasing Avatrombopag as a potentially effective and safe treatment option.

Dr. Camel's Conclusion

Avatrombopag is a promising new treatment for patients suffering from chronic ITP. It is an oasis in the desert of hematological research, offering a potential cure to a previously difficult condition. The study, conducted with a rigorous double-blind, randomized design, demonstrates Avatrombopag's efficacy and safety, paving the way for its use in clinical practice.
Date :
  1. Date Completed 2019-07-15
  2. Date Revised 2019-12-10
Further Info :

Pubmed ID

30191972

DOI: Digital Object Identifier

PMC6282556

Related Literature

Article Analysis
・Effects of avatrombopag
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.